Rift Valley Fever
1
Pipeline Programs
2
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Allergy TherapeuticsUK - West Sussex
2 programsEvidence of past or recent RVF exposureN/A1 trial
Rift Valley Fever in KenyaN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
IDBiologicsIDB-011 dose level 1
Allergy TherapeuticsEvidence of past or recent RVF exposure
Allergy TherapeuticsRift Valley Fever in Kenya
Clinical Trials (3)
Total enrollment: 5,290 patients across 3 trials
Study to Evaluate Safety, Tolerability and Pharmacokinetics of IDB-011
Start: Apr 2025Est. completion: Oct 202640 patients
Phase 1Active Not Recruiting
RVF and Other Emerging Infectious Diseases in East and Central Africa
Start: Oct 2021Est. completion: Dec 20255,000 patients
N/AUnknown
Rift Valley Fever in Kenya
Start: Mar 2006Est. completion: Apr 2006250 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.